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Zoe Moon, Rona Moss-Morris, Myra S. Hunter and Lyndsay D. Hughes 
Institute of Psychiatry, Psychology & Neuroscience, Health Psychology Section, King’s College 
London, UK 
 
Abstract 
Objective: Non-adherence to tamoxifen is common in breast cancer survivors and is 
associated with poor clinical outcomes. This study aimed to understand women’s 
experiences of taking tamoxifen and to identify factors which may be associated with 
non-adherence.  
Design: A qualitative study using semi-structured interviews.   
Methods: Thirty-two breast cancer survivors who had been prescribed tamoxifen took 
part in interviews conducted face to face or over the telephone. They were transcribed 
verbatim, and analysed using inductive thematic analysis with elements of grounded 
theory. 
Results: A key theme identified in the data was weighing up costs and benefits of 
treatment, which resulted in women falling into three groups; tamoxifen is keeping me 
alive, tamoxifen is not worth the reduced risk of recurrence, or conflicting beliefs about 
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the harms and benefits of treatment. Additional themes were living with risk of 
recurrence and information & support.  
Conclusions: Women who believed that the necessity of tamoxifen outweighed its costs 
were more likely to be adherent, whereas women who thought that the benefits did not 
outweigh the side-effects were more likely to have discontinued. A third more 
ambivalent group believed strongly in the importance of treatment, but were struggling 
with side-effects and were often non-adherent.  Patients sometimes felt unsupported and 
discussed a need for more comprehensive information. To increase adherence, future 
research needs to explore ways to increase beliefs around tamoxifen necessity and how 
to help women cope with side-effects.  
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Introduction 
Breast cancer is the most common cancer among women worldwide with around 1.7 
million women diagnosed per year (American Cancer Society, 2015). Over three 
quarters of these breast cancers are oestrogen receptor positive (ER+), which means that 
the cancer cells are stimulated by the hormone oestrogen (Harrell et al., 2007). 
Hormonal therapies (HT) such as tamoxifen are prescribed to female breast cancer 
survivors in order to reduce the risk of the cancer returning by blocking oestrogen 
receptors in cancer cells. They are one of the most effective systemic treatments for 
ER+ positive breast cancer and can almost halve the rate of recurrence (Aguilar et al., 
2010; Early Breast Cancer Trialists' Collaborative Group, 1998). Recent research has 
suggested that extending the prescription from five to ten years brings additional 
clinical benefits (Davies et al., 2013).  
Despite this, many women do not take their treatment in accordance with agreed 
recommendations from their healthcare provider which is termed as non-adherence by 
the World Health Organisation (Sabaté, 2003). Non-adherence can consist of missing or 
altering doses and/or taking medication “holidays”. Non-adherence can be intentional, 
where the patient makes a deliberate decision not to take the medication as prescribed, 
unintentional where the patient may forget or not understand the instructions, or a 
combination of both. Some women also stop treatment completely before the 
recommended duration of five to ten years, which is known as non-persistence or 
discontinuation. Both non-adherence and non-persistence are associated with increased 
risk of breast cancer recurrence and mortality (Barron, Cahir, Sharp, & Bennett, 2013; 
Hershman et al., 2011). Studies show that by the fifth year of treatment, up to 50% of 
women have discontinued (Hadji et al., 2013; Owusu et al., 2008). Adherence rates 
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range over the course of treatment from 41-88% (Murphy, Bartholomew, Carpentier, 
Bluethmann, & Vernon, 2012) and fall to 50% by the fifth year of treatment (Lee et al., 
2014; Partridge, 2003). As non-adherence and non-persistence have similar effects on 
clinical outcomes, they will both be referred to as “(non)-adherence” when discussing 
the implication of the research. This is consistent with taxonomies of adherence which 
define non-persistence as a type of non-adherence (Helmy et al., 2017; Vrijens et al., 
2012). 
 Whilst there has been an attempt to understand the reasons for non-adherence, the 
majority of research has focussed on clinical and demographic factors, with few 
consistent predictors identified (Moon et al., 2017; Murphy, et al., 2012). Improving 
adherence rates is increasingly important as tamoxifen is now being prescribed for up to 
ten years instead of five years (Burstein et al., 2014) and is recommended as 
prophylaxis for women at high risk of breast cancer (NICE, 2013).  
Tamoxifen lowers circulating oestrogen levels and as a result, is associated with a wide 
range of menopausal side effects. Hot flushes and night sweats are prevalent, occurring 
in around 80% of women taking tamoxifen (Moon et al., 2016). Other common 
menopausal side effects include loss of libido, fatigue, vaginal dryness and weight gain, 
which occur in more than one in ten women. Changes to mood and irritability are 
reported in 11% - 67% of patients taking tamoxifen (Cella & Fallowfield, 2008; Moon 
et al., 2016). Tamoxifen is often prescribed to younger, pre-menopausal women, many 
of whom would not normally be experiencing menopausal symptoms. Non-adherence is 
often assumed to be driven by these side effects (Demissie, Silliman, & Lash, 2001; 
Lash, Fox, Westrup, Fink, & Silliman, 2006), however little research has investigated 
empirically if this is the case. Whilst a small number of qualitative studies have been 
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conducted with breast cancer survivors taking adjuvant HT, researchers have 
highlighted a need to conduct more research to understand the complex problem of non-
adherence and to develop interventions to increase adherence (Harrow et al., 2014; 
Verbrugghe, Verhaeghe, Lauwaert, Beeckman, & Van Hecke, 2013). One qualitative 
study found that women struggled with their understanding of the hormonal nature of 
tamoxifen (Pellegrini et al., 2010). Another found that many women suffered side 
effects which reduced their quality of life (QOL), but did not affect adherence (Harrow, 
et al., 2014), contradicting assumptions that side-effects resulted in non-adherence. 
However, non-adherent women and those who were premenopausal were under-
represented in this study. Another study interviewed women prescribed HT and found 
that patients were surprised by the wide range of side effects they experienced (Van 
Londen et al., 2014). They were offered little support with coping with the side effects 
and had to develop strategies of their own. Verbrugghe et al. (2015) found that 
expectations regarding tamoxifen, information and social support contributed to HT 
non-adherence.   
This previous research provides insight into the experiences of women prescribed HT, 
but the studies tended to focus more on the experiences of side effects and less on 
understanding if and how non-adherence is impacted by side-effects. Furthermore, the 
majority of previous research has investigated tamoxifen jointly with aromatase 
inhibitors, which have a significantly different side effect profile (Howell et al., 2005) 
and are usually prescribed to older, post-menopausal women. More research is needed 
to understand why women may not adhere to tamoxifen treatment, in order to develop 
ways to improve adherence. This research aimed to use an inductive qualitative 
approach to elicit a broad understanding of women’s lived experiences of tamoxifen, 
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their motivation to adhere to treatment and identify reasons for non-adherence and non-
persistence, in their own words. A better understanding of adherence and non-adherence 
in this population will provide invaluable knowledge for clinicians, but will also 
contribute to the design and development of interventions to improve both adherence 
and quality of life in women taking tamoxifen.  
Methods 
Participants  
The study was approved by the Northampton National Research Ethics Committee 
(REF 14/EM/1207).  Patients were eligible if they had been prescribed tamoxifen for a 
breast cancer diagnosis, were female, over 18, spoke fluent English, and able to consent 
for themselves. Participants were recruited from a London breast clinic, local support 
centres and through online advertisements to ensure a range of menopausal status at 
diagnosis and treatment durations.  
Twenty-one women were approached in clinic and given information about the study. 
After being given two days to decide if they wanted to participate, these patients were 
contacted by the researcher. Twelve agreed to participate in the study. The remaining 
women could not be contacted. Online advertisements were placed on the following 
websites: Facebook; Macmillan Online Community; Asian Women’s Breast Cancer 
Group; and Cancer Research UK Cancer Chat. Twenty-one women responded to these 
advertisements, were screened for eligibility and given information about the study. One 
woman declined to take part and interviews were arranged with the remaining twenty 
participants. Recruitment continued until data saturation was reached, defined as the 
point at which no new themes emerged.  
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Participants were all female, aged from 36 to 77 (mean=55, SD=10.6) (Table 1). 
Treatment duration ranged from 2 months to 6 years, with a mean duration of 23 
months (SD=20). Thirty-eight percent of participants were in their first year of 
treatment.  
Procedure  
Clinic patients were told about the research by their clinician, and then introduced to a 
researcher. The researcher then gave the patient verbal information and an information 
sheet to take away. Patients were interviewed face to face in a private room or over the 
telephone. Informed consent was obtained prior to each interview. The interviews were 
based on a semi-structured interview schedule (Table 2). Questions were open ended 
and patients were encouraged to bring up issues which felt important to them. Patients 
were told that the researchers were interested in hearing their experiences regardless of 
whether they were currently taking their medication. Interviews were audio recorded 
and transcribed verbatim. Two researchers carried out the interviews.  
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Table 2 Interview schedule  
Interview Questions Prompts 
General Questions 
 
How long have you been taking tamoxifen 
for? 
Do you know which brand you were 
taking? 
When were you diagnosed with breast 
cancer?  
 
Experiences of taking tamoxifen  Side effects? How do you cope with side 
effects? 
Family life? 
Work life? 
Social life?  
Tell me about the experience of taking 
tamoxifen?  
Has anything changed over time?  
What would you change about tamoxifen?  
Adherence  How / when do you take it?  
How do you remember to take it? 
How often do you take it?  
Tell me about the practical side of taking 
tamoxifen?  
 
Knowledge about tamoxifen   
What is your understanding of why you 
are taking tamoxifen?  
How long will you keep taking tamoxifen?  
Prior beliefs / expectations 
Treatment benefits  
Concerns 
Prescription process   
Tell me about how you were prescribed 
tamoxifen?  
Who / when? 
What information were you given? 
Relationship with this person?  
Overall  
Do you have anything else to add? 
Do you have any tips for other women 
prescribed tamoxifen?  
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Data analysis 
The interviews were anonymised and pseudonyms applied before being transcribed by a 
professional transcription company. All transcripts were checked against the recordings 
for accuracy. The interviews were analysed using thematic analysis, as described by 
Braun and Clarke (2006), incorporating elements of grounded theory (Glaser & Strauss, 
2009). Data-analysis methods were chosen to optimise validity of the data and to 
develop a coherent picture of the patient’s experiences. Inductive thematic analysis is a 
theoretically flexible approach which allows in-depth exploration of interviewees’ 
experiences and perceptions with data-driven identification of patterns without 
preconceived assumptions of predefined theories or frameworks (Braun & Clarke, 
2014). Elements of grounded theory were used to develop links between themes and 
provide a richer interpretation of the data.  
After familiarisation with the data, one author generated initial codes, working 
systematically though the data set. Codes were based on language used by the 
participants and were applied to each new unit of meaning. Codes were organised into 
potential themes using thematic maps and tables following discussions with all authors. 
Themes were internally consistent, coherent and distinctive and were mapped onto the 
study aims. Following grounded theory, patterns and links between themes were 
developed in order to move beyond a purely descriptive analysis and to generate a 
theory within which to understand the data. Codes and themes were discussed within 
the research team and were modified until a coherent pattern of themes was identified. 
Transcripts were re-read to ensure the analysis was grounded in the data, that all items 
had been given equal attention and to ensure no data had been missed. Analysis was 
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iterative and involved constant comparison; a technique key to both thematic analysis 
and grounded theory which involves data, codes and themes being constantly compared.  
Characterising patients as adherent  
For the purpose of analysis, women were categorised as adherent or non-adherent 
(Table 1) based on information given in the interviews, after being explicitly asked 
about their medication taking behaviour. Women were considered adherent if they 
spoke about taking all or nearly all of their medication and non-adherent if they 
regularly skipped or halved the medication, or took treatment breaks. A few women 
self-reported having discontinued treatment. Women spoke consistently and explicitly 
about their medication taking behaviour, specifying if they forgot or skipped doses, 
which facilitated categorisation. For example, non-adherent women spoke about halving 
doses (e.g. “So I’ve had breaks off it and then I’d go on…because you’re meant to take 
twenty milligrams a day. I’d do half doses like ten milligrams instead.”) whereas 
adherent women spoke about never missing doses (e.g. “I never forget to take it.  If I 
do, everybody says have you taken your tablet, have you taken your tablet?”). Two 
researchers independently classified women and there was 100% concordance between 
ratings. Two researchers also listed side effects experienced and classified women as 
experiencing mild, moderate or severe side effects based on their discussion of the 
impact of the side effects on their QOL. Agreement was 97% for the rating of severity 
and 89% for the list of side effects experienced. All discrepancies were resolved after 
discussion. 
  
Table 1: Clinical and demographic characteristics of participants (n=32) 
Pseudonym Age 
Menopausa
l status (at 
diagnosis) 
Ethnic 
group 
Time on 
tamoxifen 
Adherence Side effects 
Sylvie 52 Post  White 2 years  Discontinued Severe: HF, mood changes, poor sleep  
Mary 49 Pre  White 6 months  Adherent   Mild  
Elisabeth 37 Unsure White 5 months  Adherent  Mild / moderate  
Arlene  62 Post  White 2 years  Adherent   Moderate / Severe  
Lisa  55 Peri White  3 months  Adherent   Moderate  
Holly 51 Peri White  4 months  Adherent   None  
Emma 45 Pre  White  
1 year, 2 
months  
Adherent   Mild  
Katie  56 Post  White  4 months  Adherent    Mild / moderate  
Hayleigh 36 Pre White  4 years  
Discontinued 
(for fertility 
reasons)   
None  
Jenny  62 Unsure 
Black 
British  
1 year  Adherent   Severe 
Julie  61 Post White  6 years  Adherent   None  
Ellen  50 Pre White 2 years  Adherent    None  
Miriam 41 Post  
Asian / 
Asian 
British 
5 years  Non-adherent  Moderate / Severe  
Michelle 77 Post  White  
2 years (then 
switched)  
Adherent   Moderate / Severe  
Shannon  55 Post  
Asian / 
Asian 
British  
5 years  Adherent Mild  
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Frances 77 Post  White 
2 years, 2 
months  
Adherent  None  
Anna 60 Post  White   2 years  Adherent  None  
Lucy 53 Post 
Black 
British  
5 years  Adherent Mild  
Lauren  62 Post White  18 months  Adherent  Mild / Moderate  
Dominique  45 Unsure  
Black 
British  
 3 years  Adherent  Mild 
Joanna  46 Unsure  
Black 
British  
1 year, 2 
months  
Adherent Mild  
Barbara 64 Post White 1 year  Non-adherent Mild / moderate  
Vanessa 63 Post White  2 years  Adherent  Mild  
Kate 52 Pre White  14 months  Non-adherent  Moderate  
Lorena 58 Post  White  1 year  
Discontinued 
(due to blood 
clots)  
Moderate / Severe 
Bonnie 61 Peri White 
4 years 8 
months  
Discontinued   Severe  
Tania 54 Peri 
British 
Indian  
 1 year, 6 
months  
Adherent Moderate  
Claudia  60 Post White  1 year Adherent  Mild  
Rosalind  44 Unsure 
Mixed 
Black / 
British 
 7 months  Adherent  Mild 
Anita 50 Peri White 2 years  Discontinued  Severe  
Marcia 54 Unsure White 2 months Adherent  None  
Celia 67 Post White   7 months  Non-adherent   Moderate / Severe  
Results 
Thirty two women were interviewed. Interviews lasted on average 44 minutes (range 
16-81). Twenty-three women were classed as adherent, four were non-adherent and five 
had discontinued. Two of the women  discontinued on their doctors’ recommendations; 
one due to blood clots and one so that she could conceive. 
Figure 1 shows the themes and subthemes identified in the data. A key theme for all 
women was the process of weighing up costs and benefits of treatment, which first 
consisted of moving from initial acceptance of treatment, and then resulted in women 
largely falling into one of three groups; tamoxifen is keeping me alive; tamoxifen is not 
worth the reduced risk of recurrence; or conflicting beliefs around the harms and 
benefits of treatment. Additional themes were living with increased risk of recurrence 
and information & support, both of which contributed to women’s beliefs about 
treatment and how they weighed these beliefs up. Each of these themes and 
corresponding subthemes will be discussed in turn.  
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Figure 1: Themes and subthemes identified in the data. Themes are represented by 
bold text and subthemes by italic text.  
 
Weighing up costs and benefits of treatment  
Moving from initial acceptance of treatment. When the women were first prescribed 
tamoxifen, they are happy to follow whatever treatment their healthcare professional 
(HCP) recommended.  
“It wasn't a choice at all. I mean they're professionals so I just listened to what 
they said.” (Barbara, 64, non-adherent) 
However, over time, some women begin to question these initial beliefs and weigh them 
up against what it is actually like to take tamoxifen. This resulted in women falling into 
Lack of 
validation with 
side effects  
Lack of support 
Lack of 
information 
Uncertainty 
Fear of 
recurrence   
Living with increased 
risk of recurrence  
Information & 
Support   
Weighing up beliefs 
about treatment  
Tamoxifen is 
keeping me alive   
Conflicting 
beliefs around 
the harms and 
benefits of 
tamoxifen 
Tamoxifen is not 
worth the 
reduced quality 
of life    
Moving from initial acceptance of treatment 
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one of three groups; those who held beliefs that tamoxifen was keeping them alive; 
those who felt that the benefits of tamoxifen were not worth the reduced QOL and those 
who had conflicting beliefs around the harms and benefits.   
Tamoxifen is keeping me alive  
Many patients held very strong beliefs regarding the necessity of taking tamoxifen. 
They felt it was incredibly important to take it every day. Whilst some patients spoke 
about wanting to avoid going through cancer treatment again, others were more 
motivated by a fear of death. Some women were also driven specifically by a desire to 
stay alive for their children.  
“Well since the option is keep taking it or be dead, it’s not much of a choice for 
me.” (Vanessa, 63, adherent)  
Some participants were less certain about the efficacy of tamoxifen, but they still felt it 
was necessary for them to keep taking it.  
“Whether like you say with me it would have come back, I just don’t know. I’d 
rather take it than not.” (Ellen, 50, adherent) 
As well as necessity beliefs, some women held strong beliefs regarding the control 
tamoxifen gave them over their risk of recurrence. They liked the fact that tamoxifen 
was a preventive measure and that it made them feel that they were actively doing 
something to prevent the cancer returning.   
“[taking tamoxifen] makes me feel better as well, because I feel like I am doing 
something actively to prevent it.” (Joanna, 46, adherent)  
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For some women these control beliefs were so strong that they were concerned about 
what would happen when their prescription ended.  
“In one way I was quite looking forward to stopping, but then as it got nearer, I 
thought, ooh, it’s like a safety blanket being taken away isn’t it?” (Julie, 61, 
adherent)  
Most women with strong necessity and control beliefs felt that they far outweighed any 
concerns they had. They were willing to experience some side effects if it meant they 
could stay alive and stop the cancer coming back.  
 “Taking tamoxifen just kind of pales into insignificance and it seems like a very 
small price to pay for not getting breast cancer again.” (Katie, 56, adherent) 
The majority of these women were experiencing no side effects or mild side effects. 
However, some did have side effects which impacted on their QOL, including anxiety, 
forgetfulness, reduced libido and hot flushes. Despite this, they were willing to keep 
taking tamoxifen as their beliefs around the necessity of tamoxifen and their desire to 
stay alive was so strong.  
“I never stopped taking it because I thought the nausea and things like that, 
come on its keeping you alive so stop moaning.” (Michelle, 77, adherent)  
In order to help them cope with the side effects, many of these women developed 
coping strategies, such as meditating, removing layers of clothing and exercising. 
Whilst the majority of women who were adherent had positive views around tamoxifen 
and were happy to keep taking the medication, one woman disconfirmed this by having 
negative emotions and beliefs about tamoxifen, yet continuing to take it. She felt that 
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tamoxifen was a reminder of the fact that despite finishing her primary treatment, she 
still cannot get on with her life.  
“I absolutely hate taking this tablet. It’s a very powerful drug. It’s not just the 
side effects. It’s a reminder of what I had.” (Lauren, 62, adherent) 
Despite this strong dislike of taking tamoxifen, this patient’s necessity beliefs and fear 
of recurrence were strong and she therefore made sure she took tamoxifen every day.   
 “I’d be too frightened to be honest not to take it.” (Lauren, 62, adherent) 
Taking tamoxifen is not worth the reduced quality of life  
Whilst some patients had strong necessity beliefs which outweighed their side effects, 
others felt that the benefits of taking tamoxifen were outweighed by the severe side 
effects they were experiencing, which led them to discontinue treatment.  
“I just couldn’t survive anymore taking it. My side effects were so bad I couldn’t 
work…When I stopped and realised the difference, there was no way I was 
going back on it.” (Bonnie, 61, discontinued)  
Patients talked about not having enough energy to participate in their lives. They could 
not maintain relationships with family members and withdrew from social activities. 
Due to side effects like severe fatigue and depression, tamoxifen had a huge impact on 
their sense of self, causing them to feel like completely different people. 
“When I was on tamoxifen, I was basically stuck in bed or sitting on the sofa 
feeling very sorry for myself. Just totally different person completely.” (Anita, 
52, discontinued) 
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Two women also experienced severe depression and suicidal thoughts. Depression was 
attributed more to the overall impact of the side effects, which mainly included fatigue, 
insomnia and muscle cramps, than directly to tamoxifen.  
 “I can’t say that tamoxifen in itself was affecting my moods, but the 
repercussions of how it [the side effects] affected my life, again it’s hard to 
unpick which was having the most effect; was it the drug itself or was it just the 
repercussions of taking it?” (Bonnie, 61, discontinued) 
One woman had a strong perception that tamoxifen was causing her to feel suicidal and 
she felt that this was the tipping point for her to discontinue.  
 “I felt so low, was having suicidal thoughts, really didn't feel like myself at all, I 
was in so much pain and that I'd made the decision that I was going to come off 
tamoxifen.” (Anita, 52, discontinued) 
These patients received little support from their healthcare teams in how to deal with the 
side effects, which exacerbated the impact on their lives. HCPs failed to acknowledge 
that the symptoms they were experiencing were related to tamoxifen and therefore did 
not offer any assistance.  
 “I actually was made to feel as if I was having like a mental breakdown...I don’t 
feel as if I was supported properly.” (Anita, 52, discontinued) 
These women still felt that tamoxifen was an effective treatment for reducing a risk of 
recurrence, but they no longer felt that the benefits of treatment were worth the side 
effects and the impact on their QOL. Participants were confident that they had made the 
right decision and were willing to risk the chance of a recurrence or death in order to 
improve their immediate QOL.  
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 “I thought actually I would rather be myself for however long that is, rather 
than be miserable for a longer period, and depending on what… whether the 
recurrence might occur or not I just thought well I’ll take that chance.” (Sylvie, 
52, discontinued)   
Conflicting beliefs around the harms and benefits of tamoxifen 
Other patients had conflicting beliefs around the harms and benefits of tamoxifen. They 
were in turmoil trying to weigh up these beliefs, and to select a behavioural outcome to 
avoid cognitive dissonance. Many of these women made the decision to skip or halve 
doses of tamoxifen.  
“I’ve got to the stage where sometimes I’ll just give it a miss…I just get so fed 
up of taking it, I just want to give myself a break.” (Miriam, 41, non-adherent)  
These patients were struggling to cope with side effects such as fatigue, joint pain, hot 
flushes and weight gain, which were having a severe impact on their QOL.  
“It [tamoxifen] is horrible. It really is the most revolting tablet I’ve ever had to 
take.” (Kate, 52, non-adherent)  
As well as struggling to cope with side effects, patients also had concerns about the 
increased risk of cancer elsewhere.  
“I worry more, not about the recurrence, but occurrence in a different part of 
my body due to this drug that I’m taking.” (Miriam, 41, non-adherent)  
In addition to this, women struggled with negative emotions around tamoxifen. For 
example, some women saw tamoxifen as a reminder of having had cancer, others had 
negative feelings relating to the impact of cancer treatment on their fertility and some 
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had strong negative feelings about tamoxifen due to their experience of side effects. 
These negative emotions caused women to attribute a lot of their symptoms to 
tamoxifen.  
 “It is a hard drug to take because of everything it does. You think tamoxifen’s 
done that, and I do blame it for a lot of things.” (Kate, 52, non-adherent)  
Despite these side effects, women wanted to keep taking tamoxifen to reduce their risk 
of recurrence.  
“If it was for anything else other than the cancer I would have stopped it, there's 
no questions, but because of the cancer is such a big thing, you know the 
possible return of it, that's the only reason I'm struggling with it” (Celia, 67, 
non-adherent) 
However they were equally as concerned about the side effects and their reduced QOL.  
 “But it’s like you’re damned if you do and you’re damned if you don't. It’s that 
worry if you don’t take it, oh god, if they find something again then I think it’s 
because I didn’t take the tamoxifen. But on the other hand it’s living with all 
these side effects on it.” (Kate, 52, non-adherent)  
Modifying their dosage allows the patient to feel like they are doing something to 
prevent the risk of cancer returning, but also allows them to exert some control over 
side effects. However, some patients felt guilty when they missed doses and ultimately 
resumed treatment if the guilt was too much, or if the fear of recurrence became too 
strong.   
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“When I don't take it I think oh, god, I should be taking it. I just feel so guilty 
when I don’t take it, but I do feel better when I’m not on it.” (Kate, 52, non-
adherent)  
Information & support  
Lack of information. Some patients felt that they were not always given 
enough information when prescribed tamoxifen. They had to do their own research on 
what to expect. Some had very basic knowledge around what tamoxifen was or why 
they were taking it.  
“I didn’t know anything about it. Really no one’s sort of explained what it is. 
They just said tamoxifen will help stopping recurrence.” (Arlene, 62, adherent)  
How informed women feel about tamoxifen is likely to influence how necessary or 
important they feel it is, which feeds in directly to the previous theme of weighing up 
beliefs about treatment. Additionally, women felt that if they had been told about what 
side effects to expect they would have been more prepared, which could then improve 
their management and experience of side effects, potentially reducing the numbers of 
women who discontinue treatment. 
Lack of support. Many women did not feel that they received the support they 
needed from their HCPs in dealing with the side effects. They would have liked to have 
been warned about how bad they could be and given emotional support in dealing with 
them. This is also linked to the previous theme of weighing beliefs about treatment, as 
this support may have helped women who were struggling with side effects, potentially 
leading them not to discontinue treatment or skip doses.  
22 
 
“I think there should be more help, psychologically, with side effects of 
tamoxifen. I think people ought to be warned.” (Kate, 52, non-adherent) 
Some patients went back to their breast clinic or GP for help with their side effects, but 
were not offered any practical coping strategies for how to reduce the impact of the side 
effects on their QOL. Patients also wanted more long term monitoring and support 
whilst they were taking tamoxifen.  
“I would like there to be more help for people who get this extreme fatigue, 
whether it's from the radiotherapy or tamoxifen.” (Celia, 67, non-adherent)   
Lack of validation with side effects. Some HCPs dismissed or belittled the side 
effects women were experiencing. Patients were told that their symptoms were not 
associated with tamoxifen, which left them feeling invalidated and frustrated.  
 “This is the one thing that I do find a lot of women struggling most with, that 
they feel so…they’re just not listened to. They’re not being validated in what 
they’re experiencing.” (Bonnie, 61, discontinued)  
Furthermore, some patients also felt that their families did not fully appreciate the 
extent of their side effects and thought the effects of tamoxifen were just linked to 
previous breast cancer.  
“I really do think my family thought that I had fallen into a depression and 
everything just because of the cancer. I think they thought that I thought I was 
going to die or I just was full of doom and gloom. But it was just out of my 
control really.” (Anita, 52, discontinued)   
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Living with increased risk of recurrence  
Fear of recurrence. Whilst most women did not identify as still having cancer, 
nearly all spoke about living in fear of cancer returning. They did not let this fear impact 
on their daily life, but said it would always be at the back of their mind. Some were not 
able to relax and were concerned that any little problem might be a sign of cancer.  
“I find it very difficult to be honest…I think the thing is anything that you find 
that you feel that is not right in your body then you start thinking ‘I wonder if 
it’s something serious’.” (Arlene, 62, adherent) 
This fear of recurrence relates to how necessary women feel that tamoxifen is for them, 
which then plays a key role in whether or not they adhere to treatment. Women who fell 
into the tamoxifen is keeping me alive group spoke about being motivated by avoiding a 
recurrence. Women who felt that tamoxifen was not worth the reduced QOL were less 
concerned about a recurrence then they were by their side effects. Most women said that 
they tried to block out this fear and not think about it. Some cited taking tamoxifen as a 
way to help them control it. Others talked about making changes to their lifestyle to try 
and be healthier. A few women felt that there was nothing they could do to control the 
risk of recurrence.  
“That would be my biggest fear is, it’s not, I suppose if it’s going to come back 
it’s possibly when, but I can’t live my life like that.  So I kind of like have to 
block it and just continue as much as I can.” (Elisabeth, 37, adherent)    
Uncertainty about recurrence. Participants reflected on the uncertainty of 
cancer regarding why it comes back or whether it will come back. They said this 
uncertainty and fear was hard to deal with.  
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“Someone said to me it’s like having a sword dangling above your head, and it 
is. You just feel like tomorrow you don’t know what’s going to happen. It’s 
always there in the back of your mind.” (Kate, 52, non-adherent)   
For women who were trying to decide whether or not to take tamoxifen, this uncertainty 
made it harder for them to make a decision.   
“I can never know what the right answer is, because I don't know whether the 
cancer will come back. I can't know until it happens.” (Celia, 67, non-adherent) 
Women who had discontinued tamoxifen were happy in their decision because they said 
they wouldn’t be able to guarantee that they wouldn’t have a recurrence of cancer even 
if they were taking tamoxifen.   
“I’ll have to deal with that if it happens, and the thing is you’ve no idea, you 
have no way of knowing if it would’ve happened anyway. I’m happy enough” 
(Bonnie, 61, discontinued)  
Discussion 
These results provide insight into the experiences of patients who initiated tamoxifen. 
Initially, women in this study were happy to take tamoxifen and did not question the 
doctor’s decision. Over time, however, they weighed up the benefits of taking 
tamoxifen against the harms, leading to some patients becoming non-adherent or non-
persistent. Women who felt that the necessity of taking tamoxifen far outweighed the 
side-effects were more likely to be adherent. Women who felt that the side effects were 
not worth the benefits were more likely to self-report discontinuing treatment. Some 
women were struggling to cope with the side effects but did not want to discontinue 
treatment due to their strong beliefs in the necessity of tamoxifen. In order to cope with 
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this and control the side effects, they skipped or halved doses. Patients in this study fell 
into one of these three distinct groups, but this may not generalise to all women.  
Whilst some women were happy with their decision to discontinue treatment, and felt it 
was the right choice for them, others were keen to continue treatment but were 
struggling with side effects, and some did not fully understand how tamoxifen helps 
them.  These latter two groups may benefit from interventions informed by the results of 
this study, such as detailing how tamoxifen works to reduce recurrence or self-
management and support for side effects. Furthermore, if we can intervene early to 
support women with side effects, we may be able to prevent patients reaching the stage 
where it is no longer worth it for them to take tamoxifen.   
Many patients felt that they were not given enough information about tamoxifen. If 
women went to their HCPs for help, they were often not given support in managing 
their side effects. Additionally, some women felt that their HCPs did not validate their 
experience of side effects. Side effects were consistent with what has been documented 
in previous literature (Boehm et al., 2009; Garreau, Delamelena, Walts, Karamlou, & 
Johnson, 2006). Some side-effects had a significant impact on women’s QOL, 
prohibiting them from working or socialising. The majority of women did not know 
how to manage these side effects, which exacerbated their impact on social, physical 
and emotional functioning. In extreme cases, the accumulation of unmanaged side 
effects led to patients feeling depressed and suicidal.  
Whilst the data was analysed using an inductive approach and a reflexive process was 
used to avoid any pre-conceived knowledge and biases, the themes that were generated 
fit well within the Self-Regulation Model of Illness Perceptions (Leventhal, Diefenbach, 
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& Leventhal, 1992) and the Necessity Concerns Framework (Horne & Weinman, 1999). 
Illness perceptions, such as perceptions around the risk of recurrence, do seem to impact 
on adherence, as do beliefs about the necessity of tamoxifen. The Necessity-Concerns 
Framework suggests that when deciding whether to take medication, patients weigh up 
their concerns against their beliefs regarding how necessary the medication is for them 
(Horne & Weinman, 1999). These beliefs have been shown to relate to HT adherence 
and persistence (Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman, 2004; Jacob Arriola 
et al., 2014). This study contributes new understanding by moving beyond the generic 
model and showing the specific beliefs held by these patients and how they influence 
behaviour. It highlights the strength of  some women’s necessity beliefs and shows the 
variability of the cost-benefit analysis across women;  some women’s’ desire to stay 
alive were so strong that they  reported tolerating any side effects whereas others would 
rather not live with the side effects despite the risk of recurrence. Women may hold 
such strong necessity beliefs because the outcome of not taking the medication is so 
serious.  
Women also had concerns about tamoxifen, but these seemed to focus almost 
exclusively on the experience of side effects, rather than other common concerns such 
as dependency. The beliefs women held were also consistent with the Self-Regulation 
Model of Illness Perceptions (Leventhal, Diefenbach, & Leventhal, 1992), which 
proposes that coping behaviours such as adherence are influenced by patient’s beliefs 
about their illness (Chilcot, Wellsted, & Farrington, 2010). Patients in this study held 
strong beliefs regarding the extent to which tamoxifen could control their risk of cancer. 
The results of this study give interesting insight into the specific illness perceptions held 
by breast cancer survivors taking tamoxifen. These women did not perceive themselves 
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as currently having cancer, but did feel at risk of a recurrence and struggled to cope with 
the uncertainty surrounding this. This fear of recurrence is what motivated women to 
continue taking their tamoxifen.  
This study suggested that side effects can cause women to discontinue treatment, which 
has been shown in several quantitative studies (Demissie, et al., 2001; Simon, Latreille, 
Matte, Desjardins, & Bergeron, 2014; Wouters et al., 2014). However, there is an 
inconsistent relationship between side effects and adherence, with some studies finding 
no significant effects (Fink, et al., 2004; Kostev et al., 2013). The results from this study 
suggest that adherence is not just related to the experience of side effects, but how 
women weigh these up against their beliefs; that is that just the experience of side 
effects is not sufficient to cause non-adherence. This may explain the inconsistent 
effects found previously. Furthermore, adherence rates may be related more to the 
perceived impact of side effects, than the side effects themselves as evidenced by the 
fact that nearly all of the women experienced side effects to some extent but most 
persisted with their tamoxifen treatment. This weighing up process is also supported by 
trade-off studies showing that women with more severe side effects needed larger gains 
in survival to make HT worthwhile (Duric et al., 2005; Thewes et al., 2005).  
Previous research has suggested that forgetting is a significant driver in HT non-
adherence (Atkins & Fallowfield, 2006). However in this study, forgetting did not seem 
to be a problem for women. Women who felt that the benefits of tamoxifen outweighed 
the side effects were motivated to keep taking it every day and established routines 
which helped them to remember. Women who missed doses reported doing so 
deliberately, such as taking breaks when on holiday or skipping doses to avoid side 
effects. Although this is based on self-reported responses and should be treated with 
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caution, non-adherence through forgetting is often more commonly self-reported than 
deliberately skipping or changing doses. This could be due to socially-desirable 
reporting and the perception that forgetting is more “acceptable” than deliberately not 
following a prescription (Atkins & Fallowfield, 2006).  
Some women did not feel that the benefits of tamoxifen were worth the reduced QOL, 
which may be related to the fact that the benefits are hidden and there is no reduction in 
symptoms which can be attributed to medication taking (Meyer, Leventhal & Gutmann, 
1985). The information women receive about their treatment and side effects is 
therefore incredibly important in increasing their necessity beliefs. All women should 
be given personalised information, so they are able to make decisions about tamoxifen 
based on the extent to which it will benefit them. Women also wanted to be warned 
about what side-effects to expect. Previous research has shown that women who 
experienced side effects they were not told about were significantly more likely to 
discontinue HT (Kahn, Schneider, Malin, Adams, & Epstein, 2007). Furthermore, 
women who receive less information about HT are less likely to initiate treatment 
(Friese et al., 2013) and more likely to take treatment breaks (Cluze et al., 2012).  
Patients also need to be informed about the importance of taking tamoxifen as 
prescribed. Some women deliberately missed or halved doses and still wanted to 
appreciate the benefits of tamoxifen. These women may not be aware that by reducing 
the dosage of tamoxifen they are reducing the effectiveness (McCowan, et al., 2008). If 
they were more educated about the implications of taking less than 80% of the 
prescribed dose, they may be more motivated to take it as prescribed.  
29 
 
Qualitative research provides a unique opportunity to understand a clinical problem 
from the patient’s perspective. This study had a large diverse sample, recruited through 
a range of locations and used in-depth interviews which enhance the richness and 
generalisability of the results. However, there were several limitations. Firstly, women 
who had chosen not to initiate tamoxifen were not included in the study. Future research 
should interview these women to understand the reasons behind their decision. Second, 
the study may have under-represented women who were non-adherent as there may be a 
selection bias where non-adherent women were less likely to respond to advertisements. 
However, there is reason to believe that women with negative experiences may also be 
biased to respond to advertisements. Twenty nine percent of participants were either 
non-persistent or non-adherent, but research shows this figure could be as high as 50% 
(Partridge, Wang, Winer, & Avorn, 2003). Including more women who were non-
adherent or non-persistent may have given further insights into what drives these 
behaviours. However, interviewing adherent women gives interesting insight into what 
motivates women to keep taking treatment, even when they are experiencing severe side 
effects. Finally, several of the women in the study had discontinued tamoxifen or had 
been taking it for some time and there may be issues of recall bias.  
Clinical implications  
Women who are given clear information about tamoxifen and how it might personally 
benefit them are in a much better position to make a decision on whether it is worth it 
for them to take it. Whilst for some women it is a logical choice to discontinue 
tamoxifen, others are keen to continue treatment but cannot cope with the side effects. 
Supporting these women may stop them from reaching the point where they have to 
discontinue. For women who are not fully informed, increasing necessity beliefs by 
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providing information may help to improve adherence rates and allows women to make 
an informed decision about continuing treatment. Patients should also be informed 
about the importance of taking tamoxifen as prescribed.  
Conclusions  
This study suggests that the main reason women are non-adherent or non-persistent with 
tamoxifen is because they are struggling with the side effects and they do not believe 
that the benefits of the treatment outweigh the side effects. Women expressed a need for 
more information about tamoxifen. Supporting women with their side effects and 
providing more information on the benefits of tamoxifen should help to increase 
adherence and improve clinical outcomes.  
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